Heidelberg Pharma AG

Regulatory Filings • Dec 13, 2007

News Details

Ad-hoc | 13 December 2007 16:23

WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX®

WILEX AG / Miscellaneous

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX announces positive result of the interim analysis for futility of its
Phase III ARISER trial with RENCAREX® ´

Munich, 13 December 2007. The Munich-based biopharmaceutical company WILEX
AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard)
announced that the Independent Data Monitoring Committee (IDMC) recommended
on the basis of the interim analysis for futility for the Phase III ARISER
trial to continue the study as planned. The analysis, which was performed
after 100 patients relapsed, showed that the trial will probably deliver a
significant result.

---

Information and Explaination of the Issuer to this News:

This communication contains certain forward-looking statements, relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
Given these uncertainties, prospective investors and partners are cautioned
not to place undue reliance on such forward-looking statements. We disclaim
any obligation to update any such forward-looking statements to reflect
future events or developments.
13.12.2007 Financial News transmitted by DGAP

---

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---